Using contrast agents to improve liver cancer radiation therapy
Official title: Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy
Run by University of Sydney · NCT05169177 · Data updated 2026-11-12
This study is testing if using special contrast agents can help doctors better track liver tumors during radiation therapy for patients who have already received a different treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | University of Sydney Academic / other |
| Drugs / interventions | radiation |
| Locations | 5 sites (Waratah, New South Wales and 4 other locations) |
| Status | Recruiting |
| Started | October 17, 2022 |
| Main results expected | October 31, 2026 |
| Study ends | October 31, 2026 |
| Registry record updated | May 19, 2026 |
| Trial ID | NCT05169177 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with liver cancer who are receiving SABR and have been administered a radio-opaque contrast agent visible on imaging scans.
✕Probably not a fit
Patients under 18 years old or those without compatible imaging datasets will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates the effectiveness of radio-opaque contrast agents in tracking liver tumors during stereotactic ablative body radiation therapy (SABR). It involves collecting image files from patients who have received SABR after trans-catheter arterial chemoembolization (TACE). The study aims to develop a software algorithm (KIM) that can accurately detect and track these contrast agents in real-time, enhancing the precision of radiation therapy. Data from 80% of participants will be used to create the algorithm, while the remaining 20% will validate its accuracy against manual delineation of tumor positions.
Why it matters
Potential benefit: If successful, this approach could significantly improve the accuracy of radiation therapy for liver cancer patients, potentially leading to better treatment outcomes.
How similar studies have gone: While the use of imaging software in radiation therapy is established, this specific approach using radio-opaque contrast agents for liver cancer tracking is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Received or will receive stereotactic ablative body radiotherapy (SABR) treatment for liver cancer at a participating site. * Received a radio-opaque contrast agent (e.g. Lipiodol™ or DC Bead LUMI™) that is visible on the radiation treatment planning CT scan * The radio-opaque contrast agent mass is or will be within the x-ray imaging field of view during the CBCT scan and any planned intra-fraction imaging. Note that there is no requirement of the distance between the contrast agent mass and the treated tumour as the goal of the study is the contrast agent mass tracking. * Provides written informed consent (prospectively recruited) or meets criteria for waiving of the requirement for consent (retrospectively recruited) Exclusion Criteria: * Less than 18 years of age * Minimum image dataset is not available * Image dataset is not in a compatible format
Where it's running
-
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia Recruiting -
Calvary Mater Newcastle Hospital
Waratah, New South Wales, Australia Not yet recruiting -
Westmead Hospital
Westmead, New South Wales, Australia Not yet recruiting -
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia Not yet recruiting -
The Austin Hospital
Melbourne, Victoria, Australia Not yet recruiting
Study contacts
- Study coordinator: Shona Silvester
- Email: Shona.Silvester@sydney.edu.au
- Phone: +61 2 8627 1185
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Variability in microwave ablation size for liver tumors
This project will see if patient and tumor features change the size and shape of microwave ablation zones in adults treated for liver tumors.
-
Predicting heart injury after major liver and biliary surgery
We test whether a stepwise prediction model using routine clinical data, the type and timing of liver blood-flow control (SPVO vs Pringle), and simple blood markers can predict heart injury (MINS) after major hepatobiliary surgery in adults.
-
Single-cell and spatial mapping of liver degeneration and regeneration
This project will try to use single-cell and spatial omics on preoperative blood and discarded liver tissue from people having liver surgery or biopsy to map how cells change during fatty liver, HBV infection, fibrosis, and cirrhosis.
-
Using contrast-enhanced ultrasound to check Y-90 radioembolization response in liver cancer
This will test whether contrast-enhanced ultrasound (CEUS) can show treatment response to Y‑90 radioembolization in people with newly diagnosed hepatocellular carcinoma who are scheduled for TARE.
-
Combining DEBIRI with chemotherapy for colorectal cancer liver metastases
This study is testing if adding a special treatment called DEBIRI to regular chemotherapy can help patients with colorectal cancer that has spread to the liver feel better and possibly have surgery later.
-
T-Cell Therapy for Advanced Liver Cancer
This study is testing a new T-cell therapy to see if it can help adults with advanced liver cancer that has a specific marker called GPC3.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.